French, P., Kros, J., de Heer, I., Eoli, M., Sepulveda, J., Walenkamp, A., . . . van den Bent, M. (2018). ACTR-47. PATIENTS WITH EGFR AMPLIFICATION BUT WITHOUT EGFRvIII EXPRESSION HAVE IMPROVED BENEFIT COMPARED TO THOSE WITH EGFRvIII EXPRESSION IN SAMPLES OF THE INTELLANCE 2/EORTC 1410 RANDOMIZED PHASE II TRIAL. Neuro Oncol.
Citação norma ChicagoFrench, Pim, et al. "ACTR-47. PATIENTS WITH EGFR AMPLIFICATION BUT WITHOUT EGFRvIII EXPRESSION HAVE IMPROVED BENEFIT COMPARED TO THOSE WITH EGFRvIII EXPRESSION IN SAMPLES OF THE INTELLANCE 2/EORTC 1410 RANDOMIZED PHASE II TRIAL." Neuro Oncol 2018.
Citação norma MLAFrench, Pim, et al. "ACTR-47. PATIENTS WITH EGFR AMPLIFICATION BUT WITHOUT EGFRvIII EXPRESSION HAVE IMPROVED BENEFIT COMPARED TO THOSE WITH EGFRvIII EXPRESSION IN SAMPLES OF THE INTELLANCE 2/EORTC 1410 RANDOMIZED PHASE II TRIAL." Neuro Oncol 2018.